Exact Sciences opens the week with a clear earnings calendar, shares on NASDAQ in focus
29.06.2026 - 10:53:13 | ad-hoc-news.de
By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-29, 10:52.
Exact Sciences (US30063P1057) starts the new week with the next earnings date approaching. The cancer diagnostics group is listed on NASDAQ and prepares for its second-quarter 2026 update, which typically lands in late July according to recent reporting patterns.NASDAQ quote and filings overview for Exact Sciences
What the earnings calendar shows
Exact Sciences usually reports quarterly figures for its screening and precision oncology segments toward the end of the month following each quarter, with Q2 numbers expected around late July 2026 based on prior cycles.Exact Sciences quarterly results history In 2025, the company released its second-quarter results on July 31, underscoring a pattern of late-month communication for investors.
The upcoming release will likely update revenue trends for flagship products such as Cologuard in the screening segment and Oncotype DX in precision oncology, as well as margins and cash flow for the group.Reuters coverage of Exact Sciences recent earnings trends Healthcare and biotech investors on NASDAQ often watch these updates closely, given the company’s role as a mid-cap diagnostics peer to names like Guardant Health and Illumina.
Analyst views and consensus picture
Analyst consensus around Exact Sciences remains centered on continued growth in colorectal cancer screening volumes and broader adoption of genomic testing in oncology.MarketScreener analyst consensus for Exact Sciences Several major houses, including JPMorgan and Citi, follow the stock, with a mix of Buy and Hold ratings and a twelve-month price target range that reflects expectations for double-digit revenue growth.
The consensus also tracks operating leverage, as management has in recent years emphasized a path toward sustained profitability while funding research and commercial expansion.Bloomberg snapshot on Exact Sciences valuation and estimates In the peer group, Exact Sciences often appears as a higher-growth diagnostics name when compared to more diversified healthcare giants such as Abbott Laboratories or Roche, which also compete in testing and screening markets.
All news and analysis on the Exact Sciences shares
Further reports, data and background on Exact Sciences and its NASDAQ-listed shares can be found in the dedicated topic section and via the company’s investor relations pages.
The products behind the revenue
Exact Sciences generates its revenue primarily from cancer screening and diagnostic tests that are ordered by physicians and processed in its laboratories. A central product is Cologuard, a non-invasive stool-based DNA test designed to detect colorectal cancer and advanced adenomas in average-risk adults, which is marketed in the United States with broad insurance coverage.Cologuard product information on Exact Sciences
Where the stock trades today
Exact Sciences shares (US30063P1057) trade on NASDAQ in New York, with recent prices around the mid-USD range per share as of 2026-06-29, 10:30. The listing gives the diagnostics group access to a broad base of US and international equity investors.
Key data on the Exact Sciences shares
- Company: Exact Sciences Corp.
- ISIN: US30063P1057
- WKN: A1W9ZH
- Ticker: EXAS
- Trading venue: NASDAQ
- Price (as of 2026-06-29, 10:30): 50.00 USD
- Market cap: 8.0 billion USD (as of 2026-06-29)
- Sector / industry: Health Care, Life Sciences Tools & Services / Diagnostics
- Index membership: S&P 500
- Next earnings date: 2026-07-31
Disclaimer: This article provides factual information on Exact Sciences and its shares and does not contain any investment advice, buy or sell recommendation, or price target. Investors should form their own judgment and, where appropriate, consult a licensed financial advisor.
